Kalaris Therapeutics, Inc.

KLRS

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Short interest: 10.7% of float.

BiotechnologyCEO: Andrew OxtobyIPO: 2020Website ↗

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Kalaris Therapeutics, Inc.

Signal Score

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research